The phase 3 CanStem111P study was terminated early due to futility.
All articles by Jen Smith
The presence of ctDNA, both at baseline and after treatment, was associated with worse survival outcomes.
There was an improvement in progression-free survival despite crossover.
Most vaccinated patients reported having mild side effects or none at all.